InvestorsHub Logo
Followers 24
Posts 1223
Boards Moderated 0
Alias Born 01/27/2021

Re: CaptBeer post# 374818

Wednesday, 04/13/2022 2:07:49 PM

Wednesday, April 13, 2022 2:07:49 PM

Post# of 430192
I'm not a doctor but I agree with CaptBeer on this one.

I'm in my 60s and my eye doctor tried to get me to take fish oil supplements or Lovaza for eyelid inflammation, whatever that is. When I asked for Vascepa instead, he of course didn't know what it was. I think I told people on this board this story and got some "find a new doctor" comments. But with only 30,000 of 750,000 doctors in the U.S. ever having prescribed it and only 6,000 to 8,000 doing so regularly, it's hard to find doctors who prescribe Vascepa, even if they've heard of it. Especially so with eye doctors.

So if what JT said is true _ that Vascepa has the safety profile of aspirin _ doctors should be more willing to readily prescribe it off-label. Didn't JT once say that more than 50 percent of people on Vascepa were prescribed off-label? Although the studies either haven't been done or haven't been extensive enough to get an expanded label, shouldn't people want to get on Vascepa to reduce plaque in arteries, possibly fight Alzheimer's and generally lower inflammation throughout the body? And that's aside from what it does to reduce changes of heart attacks and strokes.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News